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Abstract
Background: Numerous studies have identified a reduced health related quality of life (HRQL) in
patients that have either diabetes or cancer. We assessed the HRQL burden in patients with these
comorbid conditions, postulating that they would have even greater HRQL deficits.
Methods: Data from the Public Use File of the Canadian Community Health Survey (PUF CCHS)
Cycle 1.1 (September 2000–November 2001) were used for this analysis. The total sample size of
the CCHS PUF is 130,880 individuals. We used the Health Utilities Index Mark 3 (HUI3) to assess
HRQL in patients with: 1) comorbid diabetes and cancer, 2) diabetes alone, 3) cancer alone, and 4)
no diabetes or cancer. Analysis of covariance was used to compare the mean overall HUI3 score,
controlling for age, sex, marital status, body mass index (BMI), physical activity level, smoking status,
education level, depression status, and other chronic conditions.
Results:  We identified 113,587 individuals (87%) with complete data for the analysis. The
comorbid diabetes and cancer group were older and a larger proportion reported being obese,
inactive, having less than a secondary education and more chronic conditions when compared to
the other three cohorts (p < 0.0001). However, the diabetes and cancer cohort was less likely to
be depressed (p < 0.0001). Overall HUI3 scores were significantly lower for the diabetes and
cancer group (unadjusted mean (SD): 0.67 (0.30)), compared to diabetes (0.78 (0.27)), cancer (0.78
(0.25)), and the reference group (0.89 (0.18)) (p < 0.0001). After adjusting for covariates, the
comorbid diabetes and cancer group continued to have significantly lower overall HUI3 scores than
the reference group (unstandardized mean difference: -0.11, 95% CI: -0.13 to -.0.09) (p < 0.0001).
Conclusion: Individuals with diabetes and cancer had a clinically important and significantly lower
HRQL than those with either condition alone. A better understanding of the relationship between
diabetes and cancer, and their associated comorbidities, complications, and HRQL deficits may
have important implications for prevention and management strategies.
Background
Diabetes is a chronic medical condition that affects
approximately 5% of Canadians aged 20 years and older,
with type 2 diabetes accounting for 90% of all diagnosed
cases of diabetes [1]. Type 2 diabetes is associated with
several microvascular complications, such as retinopathy,
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nephropathy, and neuropathy, and macrovascular com-
plications, such as heart disease, which results in signifi-
cant morbidity and mortality [2-4]. A reduced self-
reported health status or health-related quality of life
(HRQL) reflects the significant health burden in this
patient population [5-8].
In addition to the commonly recognized micro- and mac-
rovascular complications, diabetes is associated with
other comorbidities. A number of epidemiologic studies
have identified an increased risk of developing cancer in
people with type-2 diabetes [9-12]. The association
appears to be mediated through the metabolic syndrome
(also known as the insulin resistance syndrome). The met-
abolic syndrome is present in almost one-half of all older
individuals and is a condition associated with hyperin-
sulinemia, insulin resistance and a predilection to type 2
diabetes [13].
It has been suggested that hyperinsulinemia combined
with insulin resistance might promote carcinogenesis
[14,15]. Several types of cancers have been found to be
associated with type 2 diabetes, such as breast cancer
[10,11], endometrial cancer [16,17], pancreatic cancer
[11], and colorectal cancer [11,12].
The potential HRQL deficits associated with patients who
have both type 2 diabetes and cancer may be quite large.
There is extensive evidence in the literature of a reduced
HRQL in patients with cancer [18,19]. However, despite
the recognition of the link between type 2 diabetes and
cancer, very little is known about HRQL in individuals
with these comorbid chronic conditions. The objective of
this study was to assess the HRQL burden in the following
groups: 1) Individuals with comorbid diabetes and cancer
compared to individuals with either condition alone, and
2) Individuals with comorbid diabetes and cancer com-
pared to individuals without either condition. In both
cases, we hypothesized that individuals with comorbid
diabetes and cancer would have a significantly worse
HRQL.
Methods
Canadian Community Health Survey (CCHS)
Data from the Public Use File of the Canadian Commu-
nity Health Survey (CCHS PUF) Cycle 1.1 were used for
this analysis. The CCHS contains information related to
self-reported health determinants, health care utilization,
and health status for the Canadian population. Data col-
lection for the CCHS Cycle 1.1 occurred over a two-year,
repeating cycle between September 2000 and November
2001 [20]. The CCHS targets individuals aged 12 years or
older who are living in private residences in the ten prov-
inces and the three territories. Persons living on Indian
Reserves or Crown lands, residents of institutions, full-
time members of the Canadian Armed Forces, exclusive
cellular phone users, and residents of certain remote
regions are excluded from this survey [20].
The CCHS uses a multistage stratified cluster design and a
random digit dialing sampling method for selecting their
sample [20]. The CCHS covers approximately 98% of the
Canadian population aged 12 or older. Selection of indi-
vidual respondents was designed to ensure over-represen-
tation of youths (12 to 19 years old) and seniors (65 years
or older). Each respondent was assigned a weight to rep-
resent his or her contribution to the total population. The
weights were used to derive estimates for all characteristics
surveyed [20].
Sample
The total sample size of the CCHS PUF is 130,880 individ-
uals; 113,587 individuals (86.8%) had complete data for
the analysis. Respondents were missing information for
the following variables: HUI3 (N = 1,689; 1.3%), diabe-
tes/cancer (N = 164; 0.1%), marital status (N = 162;
0.1%), BMI (N = 3,019; 2.3%), physical activity level (N =
8,461; 6.5%), smoking status (N = 139; 0.1%), education
level (N = 1,264; 1.0%), depression status (N = 3,981;
3.0%), and number of chronic medical conditions (N =
1,185; 0.9%). Several respondents had missing informa-
tion on more than one variable used in the analyses (Fig-
ure 1).
We then identified four groups of respondents, based on
self-reported chronic disease status: 1) comorbid diabetes
and cancer (unweighted N = 207; 0.2%), 2) diabetes alone
(unweighted N = 4,394; 3.9%), 3) cancer alone
Survey Sample, Analysis Sample, and Missing Data Figure 1
Survey Sample, Analysis Sample, and Missing Data.
CCHS PUF 1.1 Sample
N = 130,880
Complete HUI3
N = 129,191 (98%)
Missing Demographics
N = 15,604
Analysis Sample
N = 113,587 (87%)
Missing HUI3
N = 1,689Health and Quality of Life Outcomes 2006, 4:17 http://www.hqlo.com/content/4/1/17
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(unweighted N = 1,692; 1.5%), and 4) a reference group
without diabetes or cancer (unweighted N = 107,295;
94.5%).
Health Utilities Index Mark 3 (HUI3)
The Health Utilities Index Mark 3 (HUI3) is an indirect
preference-based measure of overall HRQL that is
included in the CCHS PUF Cycle 1.1. The HUI has been
used in hundreds of clinical studies covering a wide vari-
ety of health problems and in numerous large general
population surveys since 1990 [7,21,22]. HUI measures
have strong theoretical foundations, and are valid, relia-
ble, and well accepted by patients and professionals
[21,23,24]. The HUI3 is a useful measure for capturing
HRQL in patients with comorbid diabetes and cancer.
There is increasing evidence of the use of the HUI3 in indi-
viduals with type 2 diabetes [25-27]. There is also a sub-
stantial amount of research has used the HUI as an
outcome measure for cancer [18,19,28,29]. However,
there is no evidence in the literature of the use of the HUI
in individuals with comorbid diabetes and cancer.
The HUI3 includes a comprehensive generic health status
classification (i.e. profile) system and a utility scoring
function [30,31]. The HUI3 administered for the CCHS
Cycle 1.1 was a 31-item questionnaire. The classification
system is comprised of 8 attributes: vision, hearing,
speech, ambulation, dexterity, emotion, cognition, and
pain. Each attribute has 5 or 6 levels of functioning,
thereby defining 972,000 possible unique health states
[21]. It is important to note that the CCHS PUF has sup-
pressed the single-attribute utility scores, thus precluding
evaluation of the impact of diabetes and cancer on any
single attributes in this analysis. The overall HUI3 scoring
system provide utility (preference) scores on a generic
scale ranging from -0.36 to 1.00, where worst possible
health = -0.36, dead = 0.00, and perfect health = 1.00 [21].
Differences of 0.03 or greater in the mean overall HUI3
scores are considered clinically important [21]. Other
studies have confirmed this value as clinically important
[27,32,33]. The basis for this clinically important differ-
ence of 0.03 or greater is that a change in one level of func-
tioning on any of the eight attributes is considered to be
qualitatively important [34]. Therefore, 0.03 represents
the smallest difference in the overall score resulting from
a one level change in functioning on one attribute (e.g.
the difference in overall score between having a Level 1
and Level 2 functioning on the vision attribute) [8].
Statistical analyses
Descriptive statistics were used to compare our study
groups; comparisons were evaluated using ANOVA for
continuous variables and chi-square tests for categorical
variables. ANCOVA was used to compare the mean over-
all HUI3 score in each of the four cohorts while control-
ling for potential confounders. The following covariates
were adjusted for in the model: age, sex, marital status,
body mass index (BMI), physical activity level, smoking
status, education level, depression status (from the Com-
posite International Diagnostic Interview Short Form for
Major Depression (CIDI)), and number of chronic medi-
cal conditions other than diabetes or cancer. Income level
was not used as a covariate because there was too much
missing data (>10% of the population had missing data
on this variable). All data were from self-report.
Age was categorized into quartiles (12–29 years, 30–44
years, 45–59 years, and ≥60 years). For marital status,
individuals were categorized as "married/common-law"
or "widowed/separated/divorced/single". Respondents'
BMI was categorized as not obese (BMI < 30) or obese
(BMI ≥ 30) [35]. Physical activity level was categorized as
"active", "moderately active", or "inactive". Smoking sta-
tus was categorized as "daily", "occasionally", or "not at
all". Education level was categorized as "less than second-
ary school graduation", "secondary school graduate",
"other post-secondary school" (e.g. diploma/certificate
from a trade school, some community college), or "post-
secondary school graduate" (e.g. college or university
degree).
Respondents were categorized as "depressed" or "not
depressed" according to the Composite International
Diagnostic Interview (CIDI) Short Form for Major
Depression. Respondents who had a predicted probability
of 0.90 or greater for major depression on the CIDI were
considered to have depression [36]. This is in accordance
with the DSM-IV diagnostic criteria for a major depressive
disorder [36]. Depression is an important comorbidity to
include in the analyses, as it has been linked to a reduced
HRQL in patients with diabetes and in patients with can-
cer [37,38]. Lastly, number of chronic medical conditions
other than diabetes or cancer was categorized as follows:
0, 1, 2, or ≥3 chronic conditions. For all comparisons, a p-
value of less than 0.05 (two-tailed) was considered to be
statistically significant. Normalized sampling weights
were used in the analysis to account for unequal selection
probability. All statistical analyses were performed using
SPSS Version 13.0.
Results
In our sample of 113,587 individuals, all of the patient
characteristics were significantly different for the four
groups (Table 1). In general, the comorbid diabetes and
cancer group tended to be older (70.4% of respondents
were ≥60 years old) compared to the others. There were
significantly fewer men in the cancer alone group (43.7%)
compared to the other groups, where men represented
approximately 50% of the population. ApproximatelyHealth and Quality of Life Outcomes 2006, 4:17 http://www.hqlo.com/content/4/1/17
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one-third of respondents were obese (BMI ≥ 30) in the
comorbid diabetes and cancer and the diabetes groups. A
significantly larger proportion of patients reported being
inactive and having less than a secondary education in the
comorbid diabetes and cancer and the diabetes groups,
compared to the cancer alone or the reference group.
Interestingly, the reference group responded that they
smoked more frequently than the others (approximately
27% of respondents were daily or occasional smokers).
The cancer group had a significantly larger proportion of
individuals who were considered to be depressed
(12.5%). Lastly, the diabetes and cancer group self-
reported more chronic conditions than the other groups.
The unadjusted mean (standard deviation, SD) overall
HUI3 for the comorbid diabetes and cancer group was
0.67 (0.30). This value was significantly lower than that
for the other groups: 0.78 (0.27) for diabetes alone, 0.78
(0.25) for cancer alone, and 0.89 (0.18) for the reference
group (Table 1).
After adjusting for the covariates, the comorbid diabetes
and cancer group had a significantly lower overall HUI3
score compared to the reference group, which served as
the reference group (mean difference: -0.11, 95% CI: -0.13
to -0.09; Table 2). As hypothesized, the comorbid diabe-
tes and cancer group also had a significantly lower HUI3
Table 1: Patient Characteristics Stratified by Disease Group (N = 113,587)
Diabetes and Cancer (*N = 
207))
Diabetes (*N = 4,394) Cancer (*N = 1,692) No Diabetes or Cancer 
(*N = 107,295)
HUI3 (Overall Score)**
Mean (Standard 
Deviation, SD)
0.67 (0.30) 0.78 (0.27) 0.78 (0.25) 0.89 (0.18)
Median (Range) 0.78 (-0.24 – 1.0) 0.91 (-0.31 – 1.0) 0.91 (-0.21 – 1.0) 0.97 (-0.31 – 1.0)
Age (Years), (%)†
12–29 Years 2 (1.0%) 144 (3.3%) 81 (4.8%) 32,018 (29.8)
30–44 Years 4 (1.9%) 554 (12.6%) 189 (11.2%) 32,708 (30.5%)
45–59 Years 55 (26.7%) 1,325 (30.2%) 446 (26.4%) 24,933 (23.2%)
≥60 Years 145 (70.4%) 2,370 (53.9%) 976 (57.7%) 17,636 (16.4%)
Men, (%)† 114 (55.3%) 2,256 (51.3%) 740 (43.7%) 51,726 (48.2%)
BMI, (%)†
<30 139 (67.1%) 2,873 (65.4%) 1,442 (85.2%) 93,511 (87.2%)
≥30 68 (32.9%) 1,520 (34.6%) 250 (14.8%) 13,784 (12.8%)
Marital Status, (%)†
Married/Common Law, 
(%)
147 (71.4%) 2,933 (66.8%) 1,143 (67.6%) 61,595 (57.4%)
Widowed/Separated/
Divorced/Single
59 (28.6%) 1,461 (33.2%) 549 (32.4%) 45,700 (42.6%)
Physical Activity Level, (%)†
Active 29 (14.0%) 663 (15.1%) 330 (19.5%) 25,257 (23.5%)
Moderately Active 26 (12.6%) 937 (21.3%) 368 (21.8%) 25,542 (23.8%)
Inactive 152 (73.4%) 2,794 (63.6%) 993 (58.7%) 56,496 (52.7%)
Education Level, (%)†
<Than Secondary 95 (45.9%) 1,806 (41.1%) 544 (32.2%) 29,837 (27.8%)
Secondary Graduate 21 (10.1%) 743 (16.9%) 313 (18.5%) 20,204 (18.8%)
Other Post-Secondary 14 (6.8%) 270 (6.1%) 95 (5.6%) 9,151 (8.5%)
Post-Secondary 
Graduate
77 (37.2%) 1,574 (35.8%) 740 (43.7%) 48,102 (44.8%)
Smoking Status, (%)†
Daily 38 (18.4%) 734 (16.7%) 271 (16.0%) 23,527 (21.9%)
Occasionally 3 (1.4%) 117 (2.7%) 51 (3.0%) 5,066 (4.7%)
Not At All 166 (80.2%) 3,542 (80.6%) 1,369 (81.0%) 78,703 (73.4%)
Depressed, (%)† 10 (4.8%) 342 (7.8%) 212 (12.5%) 7,837 (7.3%)
Number of Chronic 
Conditions, (%)†
0 8 (3.9%) 675 (15.4%) 305 (18.0%) 40,775 (38.0%)
1 26 (12.6%) 1,002 (22.8%) 360 (21.3%) 29,471 (27.5%)
2 30 (14.6%) 864 (19.7%) 314 (18.6%) 17,977 (16.8%)
≥3 142 (68.9%) 1,853 (42.2%) 712 (42.1%) 19,072 (17.8%)
*Unweighted N (All other values in the table are weighted).
**P < 0.0001 for Analysis of Variance (ANOVA)
†P < 0.0001 for Chi-square testHealth and Quality of Life Outcomes 2006, 4:17 http://www.hqlo.com/content/4/1/17
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than the diabetes (mean difference: -0.04, 95% CI: -0.05
to -0.04) and the cancer (mean difference: -0.04, 95% CI:
-0.05 to -0.03) groups. All of these between group differ-
ences would be considered clinically important.
Respondents who were younger, married/common law,
physically active, not obese, not depressed, and had no
chronic medical conditions had significantly higher over-
all HUI3 scores (Table 2). On the other hand, males,
smokers, or respondents that had not completed high
school had significantly lower overall HUI3 scores (Table
2). Of note, there were clinically important differences in
the following variables for overall HUI3 score: age, physi-
cal activity level, education level, depression status, and
number of chronic medical conditions (Table 2).
Table 2: Weighted ANCOVA for HUI3 by Disease Group
B* (Unstandardized Mean 
Difference)
95% Confidence Interval (Lower – Upper)
Diabetes/Cancer**
Diabetes and Cancer -0.108† -0.131 -0.086
Diabetes -0.040† -0.045 -0.035
Cancer -0.040† -0.048 -0.033
No Diabetes Or Cancer reference - -
Age**
12–29 Years 0.056† 0.052 0.059
30–44 Years 0.038† 0.035 0.041
45–59 Years 0.021 0.018 0.024
≥60 Years reference - -
Sex**
Male -0.011 -0.013 -0.009
Female reference - -
Marital Status**
Married/Common Law 0.023 0.021 0.025
Widow/Separated/Divorced/
Single
reference - -
Physical Activity Level**
Active 0.038† 0.036 0.041
Moderately Active 0.032† 0.029 0.034
Inactive reference - -
Education Level**
<Than Secondary Education -0.040† -0.043 -0.038
Secondary Education Graduate -0.011 -0.014 -0.009
Other Post-Secondary 
Education
-0.011 -0.015 -0.007
Post-Secondary Education 
Graduate
reference - -
Smoking Status**
Daily Smoker -0.020 -0.023 -0.018
Occasional Smoker -0.011 -0.016 -0.007
Not At All reference - -
BMI**
<30 0.015 0.012 0.018
≥30 reference - -
Depression Status**
Not Depressed 0.142† 0.138 0.145
Depressed reference - -
Number of Chronic Conditions**
00 . 1 4 9 † 0.146 0.152
10 . 1 2 7 † 0.124 0.130
20 . 0 9 4 † 0.091 0.097
≥3 reference - -
*Adjusted for all other covariates in the table
**All variables were statistically significant, P < 0.0001
†Clinically meaningful difference of ≥0.03Health and Quality of Life Outcomes 2006, 4:17 http://www.hqlo.com/content/4/1/17
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Discussion
We used population-based data from the Canadian Com-
munity Health Survey Cycle 1.1 to determine HRQL,
using the overall HUI3 score, in respondents with self-
reported diabetes and cancer compared to a reference
group without diabetes or cancer. As hypothesized, we
found that patients with diabetes and cancer had a signif-
icantly lower and clinically important difference in overall
HUI3 score compared to respondents who had no diabe-
tes or cancer, even after controlling for potential con-
founding variables.
All covariates included in the model were associated with
significant differences in overall HRQL; however, not all
of the variables revealed clinically important differences.
Number of chronic medical conditions and specific
comorbidities, such as depression, had the largest impact
on HRQL. Respondents who were not depressed had a
0.14 higher HUI3 overall score compared to respondents
who were depressed. Also, the fewer chronic medical con-
ditions apart from diabetes and cancer that respondents
had, the higher their overall HUI3 score (0.15 for no
chronic medical conditions compared to respondents
who had 3 or more chronic medical conditions). These
findings are in agreement with Maddigan et al, who found
that comorbidities such as cardiovascular disease and
depression had the largest impact on HRQL in patients
with type 2 diabetes [7,8].
Previous research has reported lower overall HUI3 scores
in individuals that have either type 2 diabetes [7,25] or
cancer [18,19]. These deficits are likely a result of the com-
plications, comorbidity, and treatment regimens associ-
ated with these chronic conditions. There is strong
evidence of an association between type 2 diabetes and
cancer; this association appears to be mediated through
the metabolic syndrome [9-11]. Furthermore, there is an
increased mortality for patients with comorbid diabetes
and cancer [9,39]. Despite these associations, however,
very little is known about the HRQL deficits in this patient
population.
The overall HUI3 scores we observed in our sample are
similar to that of other studies. A study by Maddigan et al,
observed the same mean overall HUI3 score of 0.78 in
patients with type 2 diabetes as our study did in patients
that have diabetes; this finding is not surprising consider-
ing the authors also used CCHS data [32]. They also
observed mean overall HUI3 scores of 0.77 for arthritis
patients (a figure similar to the 0.78 we found for our can-
cer group), 0.54 for patients who have had a stroke, and
0.90 for the general population (a figure similar to the
0.89 we found for our reference group that did not have
diabetes or cancer) [32].
There are some limitations inherent in this study. Firstly,
the cross-sectional study design of the CCHS is not ideal
Table 3: 
CCCA_011 (We are interested in long-term conditions that have lasted or are expected to last 6 months or more and that have been 
diagnosed by a health professional). Do you have food allergies?
CCCA_021 Do you have any other allergies?
CCCA_031 Do you have asthma?
CCCA_041 (Remember, we're interested in conditions diagnosed by a health professional). Do you have fibromyalgia?
CCCA_051 Do you have arthritis or rheumatism excluding fibromyalgia?
CCCA_061 (Remember, we're interested in conditions diagnosed by a health professional). Do you have back problems, excluding 
fibromyalgia and arthritis diagnosed by a health professional?
CCCA_071 Do you have high blood pressure?
CCCA_081 Remember, we're interested in conditions diagnosed by a health professional. Do you have migraine headaches?
CCCA_91A (Remember, we're interested in conditions diagnosed by a health professional). Do you have chronic bronchitis?
CCCA_91B Do you have emphysema or chronic obstructive pulmonary disease (COPD)?
CCCA_101 Do you have diabetes?
CCCA_111 Do you have epilepsy?
CCCA_121 Do you have heart disease diagnosed by a health professional?
CCCA_131 Do you have cancer?
CCCA_141 (Remember, we're interested in conditions diagnosed by a health professional). Do you have stomach or intestinal ulcers?
CCCA_151 Do you suffer from the effects of a stroke?
CCCA_161 Do you suffer from urinary incontinence?
CCCA_171 Do you have a bowel disorder such as Crohn's Disease or colitis?
CCCA_191 Do you have cataracts?
CCCA_201 Do you have glaucoma?
CCCA_211 Do you have a thyroid condition?
CCCA_251 Remember, we're interested in conditions diagnosed by a health professional. Do you have chronic fatigue syndrome?
CCCA_261 Do you suffer from multiple chemical sensitivities?
CCCAG221 Has other chronic conditionHealth and Quality of Life Outcomes 2006, 4:17 http://www.hqlo.com/content/4/1/17
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for the purpose of answering this question. A longitudinal
study design would more appropriately address this ques-
tion, as changes in HRQL over time could also be
assessed. Since both are chronic conditions, however, the
duration of follow-up would be prohibitive. Furthermore,
as a cross-sectional study, in conditions which have sub-
stantial mortality such as cancer, there is likely a survival
bias and respondent bias, with only those more healthy
individuals in the community being respondents. This
would, of course, lead to an over estimate of the respond-
ents in the cancer groups.
We also lacked information on potentially useful clinical
variables. Recent research has revealed that waist circum-
ference or waist to hip ratio may be more effective than
BMI in predicting risk for type 2 diabetes or cancer
[40,41]. Furthermore, there is evidence that obesity, as
measured by waist to hip ratio and/or waist circumfer-
ence, are associated with various measures of HRQL
[42,43]. It would also be useful to have clinical informa-
tion on the different types of cancer and on disease sever-
ity for both diabetes and cancer, all of which would
differentially impact the HRQL of individuals [26].
Although type of cancer and a variable that allows calcu-
lation of time since cancer diagnosis are collected as part
of the CCHS Cycle 1.1 microdata, these variables are not
available in the CCHS PUF.
Another limitation of this dataset was the inability to sep-
arate the diabetes cohort into type 1 diabetes and type 2
diabetes. The group with type 2 diabetes may have been of
particular interest, as there is well-documented evidence
of an increased risk of various types of cancer in patients
with type 2 diabetes [10-12,17]. However, there is no lit-
erature to support the evidence of a link between type 1
diabetes and cancer, and we could expect that approxi-
mately 10% of the diabetes cohort has type 1 diabetes
[1,8]. Insulin use is available in the CCHS PUF, there is a
substantial amount of missing data on this variable
(95.2% or 124,609/130,880). Also, because the variables
in the CCHS are self-reported, there is a potential for recall
bias or social desirability bias. For example, there is evi-
dence that respondents may respond in a socially desira-
ble manner when self-reporting their BMI (height and
weight) [44], smoking status [45], and physical activity
status [46].
We recognize that the PUF version of the CCHS data is not
as precise as the micro data available through Statistics
Canada. In the PUF, some data elements are aggregated,
and variables that have been collapsed, and more impor-
tantly there is no information on the single attribute util-
ity scores from the HUI3. There were also missing data on
a number of the covariates (particularly for physical activ-
ity level, 6.5%; depression status, 3.0%; and BMI 2.3%).
We noted that respondents with missing data on any of
these three variables were younger and had lower overall
HUI3 scores. There was no relationship between missing
BMI and reporting diabetes or cancer. Respondents with
cancer were more likely to be missing data on physical
activity, although the differences were small. Respondents
with both diabetes and cancer were more likely to be miss-
ing data on depression. As such, excluding these individu-
als likely overestimated the HUI3 scores across all groups.
Of note, the diabetes and cancer group was most likely to
have had missing data on depression; had those individu-
als been included, the overall HUI3 score would have
been even lower. One variable in particular that had a sub-
stantial amount of missing data (>10% for all respond-
ents) was income; therefore, this variable was not
included in our analyses. It has been shown that income,
as a determinant of health, is a distinct aspect of socioeco-
nomic status that is useful in predicting HRQL, independ-
ent of education level [47].
Despite the above mentioned limitations in this study,
there are some key strengths that must be recognized.
Most importantly, the CCHS has a very large sample that
is considered to be representative of 98% of the Canadian
population. Also, we used the HUI3 as our measure of
HRQL. There is evidence of the validity of this measure in
people who have type 2 diabetes [27] and in people who
have cancer [48]. It has also been used in other large
national population health surveys [7,21,22]. Finally, to
our knowledge, this is the first study that has assessed
HRQL, using the HUI3 as an outcome measure, in
patients who have comorbid diabetes and cancer.
Conclusion
We found that patients with comorbid diabetes and can-
cer had a clinically meaningfully worse overall HUI3 score
compared to respondents who had no diabetes or cancer,
differences which were considerable, even after control-
ling for potential confounding variables. While our results
are intriguing, they should be considered hypothesis-gen-
erating given the limitations inherent in this study. Diabe-
tes (especially type 2 diabetes) and cancer are largely
preventable through lifestyle. Separately, the public
health burden of these two chronic diseases is large;
together their burden is even greater. A better understand-
ing of the relationship between diabetes and cancer, and
their associated comorbidities and complications may
have important implications for prevention and manage-
ment of these chronic conditions. These prevention and
management strategies will in turn have positive effects
on the HRQL of individuals affected by these conditions.
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